News – Page 987 – Endpoints News

Ramping up in-house drug development, API maker BrightGene bags $80M round led by Sequoia China

7 years ago

With mega merger season in full swing, Takeda officially swallows Shire

7 years ago

Liz Barrett's bet on UroGen proves timely, as biotech's lead drug scores in key study

7 years ago

Billed as potential blockbuster, Novartis' sickle cell drug scores FDA's breakthrough therapy status

7 years ago

FDA has about one month of user fee funds left, Gottlieb warns

7 years ago

Championed by AbbVie, immuno-neurology player Alector maps $150M IPO

7 years ago

Positive ocular implant data bring Allergan one step closer to NDA; Vivek Ramaswamy spawns another 'Vant'

7 years ago

Prepping a cross-Pacific move, OrbiMed-backed Apollomics bags $100M Series B for I/O combos

7 years ago

Sage shrugs off potential competition in postpartum depression, asserts plan to remain independent

7 years ago

Cheerful mid-stage depression drug data send Axsome stock flying

7 years ago

AstraZeneca names controversial cancer scientist José Baselga to a top R&D post in major shakeup

7 years ago

TCR deal spree intensifies as Roche commits up to $2B in Adaptive Biotech to develop personalized cancer drugs

7 years ago

Allergan joins the great biopharma R&D migration to Cambridge

7 years ago

Sage's oral postpartum depression drug ticks efficacy, safety boxes in key trial, easing fears of fainting risk

7 years ago

#JPM19 starts with Eli Lilly's $8B buyout of Loxo Oncology — so who's next?

7 years ago

Shifting focus, Sanofi agrees to pay Regeneron $462M for an early wrap of their big I/O alliance

7 years ago

Gilead stuffs another NASH drug discovery program into a growing portfolio

7 years ago

Bill Gates backs Schrödinger's $85M venture raise for its standout computational drug discovery platform

7 years ago

Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T

7 years ago

Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly

7 years ago

How much does it cost to hire a top Big Pharma exec to run a biotech? Here are 4 (very) fresh examples

7 years ago

Atara seeks new CEO as Isaac Ciechanover exits; AstraZeneca's Mark Mallon tapped to replace Peter Hecht at Ironwood

7 years ago

Aimmune enters into loan agreement with KKR; Boehringer bags rights to second RNAi drug from Dicerna

7 years ago

Scoop: MedImmune chief Bahija Jallal is leaving AstraZeneca and joining the trek into biotech

7 years ago

First page Previous page 984 985 986987988 989 990 Next page Last page